tiprankstipranks
Advertisement
Advertisement

AU:CHM Stock Latest News

Chimeric Therapeutics Flags Risks Around Forward-Looking Cell Therapy Statements
Company AnnouncementsChimeric Therapeutics Flags Risks Around Forward-Looking Cell Therapy Statements
5d ago
CHM
Chimeric Therapeutics to Showcase Cancer Cell Therapy Pipeline at NWR Virtual Healthcare Conference
PremiumCompany Announcements
Chimeric Therapeutics to Showcase Cancer Cell Therapy Pipeline at NWR Virtual Healthcare Conference
7d ago
CHM
Chimeric Therapeutics Launches Complex Capital Raising via Prospectus
PremiumCompany Announcements
Chimeric Therapeutics Launches Complex Capital Raising via Prospectus
7d ago
CHM
Chimeric Therapeutics Restructures Warrant Issue With Unchanged Total Value
PremiumCompany Announcements
Chimeric Therapeutics Restructures Warrant Issue With Unchanged Total Value
11d ago
CHM
Chimeric Therapeutics to Consolidate Shares and Equity Securities
PremiumCompany Announcements
Chimeric Therapeutics to Consolidate Shares and Equity Securities
11d ago
CHM
Chimeric Therapeutics Sets Hybrid Extraordinary General Meeting for April 2026
PremiumCompany AnnouncementsChimeric Therapeutics Sets Hybrid Extraordinary General Meeting for April 2026
11d ago
CHM
Chimeric’s New Chair Refocuses Strategy Around Lead GI Cancer Cell Therapy
Premium
Company Announcements
Chimeric’s New Chair Refocuses Strategy Around Lead GI Cancer Cell Therapy
24d ago
CHM
Chimeric Therapeutics Secures $1.8m Advance on FY26 R&D Tax Incentive
Premium
Company Announcements
Chimeric Therapeutics Secures $1.8m Advance on FY26 R&D Tax Incentive
28d ago
CHM
Chimeric Therapeutics Posts Wider Half-Year Loss as Auditor Flags Going Concern Risk
PremiumCompany Announcements
Chimeric Therapeutics Posts Wider Half-Year Loss as Auditor Flags Going Concern Risk
1M ago
CHM
Chimeric Hands Back CHM CLTX to City of Hope to Sharpen Focus on Core Cell Therapy Programs
PremiumCompany Announcements
Chimeric Hands Back CHM CLTX to City of Hope to Sharpen Focus on Core Cell Therapy Programs
1M ago
CHM
Chimeric Clarifies ASX Query on CORE NK Trial Disclosures
PremiumCompany Announcements
Chimeric Clarifies ASX Query on CORE NK Trial Disclosures
1M ago
CHM
Chimeric Therapeutics Revises Terms and Timing of Convertible Note Issue
PremiumCompany Announcements
Chimeric Therapeutics Revises Terms and Timing of Convertible Note Issue
1M ago
CHM
Chimeric Therapeutics Secures Funding to Complete Phase 1 CAR‑T Trial and Launches Strategic Reset
PremiumCompany AnnouncementsChimeric Therapeutics Secures Funding to Complete Phase 1 CAR‑T Trial and Launches Strategic Reset
1M ago
CHM
Chimeric Therapeutics Posts Strong CDH17 CAR‑T Data and Gains FDA Orphan Status for Gastric Cancer
Premium
Company Announcements
Chimeric Therapeutics Posts Strong CDH17 CAR‑T Data and Gains FDA Orphan Status for Gastric Cancer
2M ago
CHM
Chimeric Therapeutics Issues 309.9 Million New Shares Under Regulatory Notice
Premium
Company Announcements
Chimeric Therapeutics Issues 309.9 Million New Shares Under Regulatory Notice
3M ago
CHM
Chimeric Therapeutics Seeks ASX Quotation for 309.9 Million New Shares
PremiumCompany Announcements
Chimeric Therapeutics Seeks ASX Quotation for 309.9 Million New Shares
3M ago
CHM
Chimeric Therapeutics Announces Change in Substantial Holding After Share Placement
PremiumCompany Announcements
Chimeric Therapeutics Announces Change in Substantial Holding After Share Placement
3M ago
CHM
Chimeric Therapeutics Issues 466.7 Million New Shares Under Section 708A
PremiumCompany Announcements
Chimeric Therapeutics Issues 466.7 Million New Shares Under Section 708A
3M ago
CHM
Chimeric Therapeutics Seeks ASX Quotation for 466.7 Million New Shares
PremiumCompany Announcements
Chimeric Therapeutics Seeks ASX Quotation for 466.7 Million New Shares
3M ago
CHM
Chimeric Therapeutics Plans Major Capital Raise via Shares, Notes and Options
PremiumCompany AnnouncementsChimeric Therapeutics Plans Major Capital Raise via Shares, Notes and Options
3M ago
CHM
Chimeric Therapeutics Issues 16.7 Million Unquoted Options Under Employee Incentive Scheme
Premium
Company Announcements
Chimeric Therapeutics Issues 16.7 Million Unquoted Options Under Employee Incentive Scheme
3M ago
CHM
Chimeric Therapeutics Grants 16.7 Million Unlisted Options to Director Miles Prince
Premium
Company Announcements
Chimeric Therapeutics Grants 16.7 Million Unlisted Options to Director Miles Prince
3M ago
CHM

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >